Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03433040 · ClinicalTrials.gov registry record · Phase 3

17OHP-C Dosing Among Obese Pregnant Women

A Phase 3 study of Premature Birth and Absorption; Chemicals, sponsored by University of South Florida.

Completed
Registry status
Phase 3
Development phase
44
Enrollment target
2
Study locations

NCT03433040: Completed Phase 3 study of Premature Birth and Absorption; Chemicals, sponsored by University of South Florida.

NCT03433040 is a Phase 3 study of Premature Birth and Absorption; Chemicals that has completed, run by University of South Florida. The registered enrollment target is 44 participants, below the 393-participant average among 38 other Premature Birth trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03433040, a Phase 3 study of Premature Birth and Absorption; Chemicals, has completed, sponsored by University of South Florida.

COMPLETED
Registry status
Phase 3
Development phase
44 participants
Enrollment target
2
Study locations

Study Summary

Emergency data suggest 17OHP-C may be less efficacious in obese women. Since obesity is associated with lower levels of plasma 17OHP-C, the investigator hypothesize that higher doses of 17OHP-C may help to prevent spontaneous PTB among obese women. The study aims to compare the pharmacokinetics of 17 OHP-C in obese compared with non-obese women.

Primary Outcome

Blood levels

Interventions

  • DRUG 17-Hydroxyprogesterone Capronate

Study Locations (2)

Florida

  • University of South Florida - Tampa

Missouri

  • Washington University in St Louis - St Louis

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2017-08-23
Est. Completion 2021-07-14
Phase Phase 3
University of South Florida

252 total trials

What the finished NCT03433040 record still lists

NCT03433040 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 393-participant average among 38 other Premature Birth trials with a reported enrollment target (89% lower).

The record links to 2 conditions, with Premature Birth appearing as the primary indexed condition, and to 1 intervention - of which 17-Hydroxyprogesterone Capronate is the first listed.

NCT03433040 reports a single indexed study location in Florida, Missouri.

Frequently Asked Questions

What is clinical trial NCT03433040 about?

NCT03433040 is a clinical study titled "17OHP-C Dosing Among Obese Pregnant Women". Emergency data suggest 17OHP-C may be less efficacious in obese women. Since obesity is associated with lower levels of plasma 17OHP-C, the investigator hypothesize that higher doses of 17OHP-C may help to prevent spontaneous PTB among obese women. The study aims to compare the pharmacokinetics of 1...

What is the current status of trial NCT03433040?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2017-08-23. Estimated completion is 2021-07-14.

What conditions does trial NCT03433040 study?

This clinical trial studies the following conditions: Premature Birth, Absorption; Chemicals.

What interventions are being tested in trial NCT03433040?

The interventions under investigation include: 17-Hydroxyprogesterone Capronate (DRUG).

Who is sponsoring clinical trial NCT03433040?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03433040 being conducted?

This trial has 2 study locations across Florida, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Premature Birth

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03433040's enrollment target sits among peer trials

44 33rd of 38 higher than 6 of 38 other Premature Birth trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Premature Birth trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03433040, the US trial registry maintained by the National Library of Medicine. NCT03433040 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.